ARS Pharmaceuticals (SPRY) Stock Price, News & Analysis

ARS Pharmaceuticals, Inc. (Nasdaq: SPRY) is a commercial-stage biopharmaceutical company in the pharmaceutical preparation manufacturing industry. According to the company’s public statements, ARS Pharma is dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The company is focused on developing and commercializing intranasal epinephrine products for emergency treatment of Type I allergic reactions, including anaphylaxis.

The company’s primary product is neffy®, an epinephrine nasal spray. Press releases state that neffy is indicated in the United States for the emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients 4 years of age and older who meet specified weight thresholds. In Europe, under the trade name EURneffy®, neffy is indicated for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens, as well as idiopathic or exercise-induced anaphylaxis in certain adult and pediatric weight groups. In China, neffy is approved under the trade name 优敏速® for the emergency treatment of Type I allergic reactions (anaphylaxis) in adults and children who weigh 30 kg or more.

Based on company disclosures, neffy is a nasal spray formulation of epinephrine designed for needle-free administration. The company describes neffy as a product intended for use in the nose only, with each device containing a single dose of epinephrine for emergency treatment. neffy is described as easy to carry and simple to use, with characteristics such as a compact form factor and temperature excursions up to 122°F (50°C), and the ability to be used after thawing if accidentally frozen, without damage to the device or product within, as stated in ARS Pharma’s communications.

According to ARS Pharma, neffy is commercially available in the U.S. for emergency treatment of allergic reactions, including anaphylaxis, in adults and children aged 4 years and older who weigh at least 33 pounds (15 kg). The company also reports that its European partner ALK has launched EURneffy in Europe and the U.K. In Japan, ARS Pharma has entered into an exclusive licensing agreement with Alfresa Holdings, which holds rights to commercialize neffy; Japanese regulators have approved neffy 1 mg and 2 mg doses for the emergency treatment of allergic reactions (anaphylaxis) in adults and children who weigh greater than 15 kilograms. In China, ARS Pharma has an exclusive licensing agreement with Pediatrix Therapeutics, which has rights to market neffy under the trade name 优敏速®, with regulatory approval granted for neffy 2 mg for adults and children who weigh 30 kg or more.

Company materials also describe a broader intranasal epinephrine program. ARS Pharma reports that it is conducting a Phase 2b clinical trial to evaluate intranasal epinephrine technology as a treatment for acute flares in patients with chronic spontaneous urticaria. The company notes that this trial is enrolling patients in the U.S. and Europe. In addition, ARS Pharma references a post-marketing, registry-based randomized, controlled study of neffy for the treatment of anaphylaxis in oral food challenge or allergen immunotherapy clinics in the United States.

ARS Pharma emphasizes the clinical context of Type I allergic reactions and anaphylaxis in its public information. The company cites that Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, which it describes as the only FDA-approved medication for these reactions. Company communications also discuss published limitations associated with epinephrine auto-injectors, including fear of needles, portability issues, needle-related safety concerns, device complexity, and resulting delays or failures in administration. Within this context, ARS Pharma positions neffy as a needle-free epinephrine option that may address some of these barriers to timely treatment.

In multiple press releases, ARS Pharma highlights real-world data and scientific presentations related to neffy. The company reports that real-world treatment outcomes presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting showed that about 90% of patients experiencing anaphylaxis were effectively treated with a single dose of neffy, and that these outcomes were described as indistinguishable from historically reported epinephrine injection in the cited analysis. ARS Pharma also notes a series of poster presentations and case reports that explore topics such as patient anxiety and well-being related to intranasal epinephrine versus auto-injectors, the effect of sniffing after dosing, survey data from patients prescribed epinephrine nasal spray, ocular safety after unintentional exposure, rationale for a second dose to the same nostril, and stability of epinephrine nasal spray under freeze, thaw and extreme temperatures.

From an intellectual property standpoint, ARS Pharma discloses that it holds patents related to nasal spray epinephrine formulations and methods of use. The company reports that the Opposition Division of the European Patent Office upheld the validity of all claims in a European patent directed to nasal spray epinephrine formulations including alkyl-glycoside, such as Intravail®, and uses thereof, with coverage validated in over 30 European countries. ARS Pharma also notes that the United States Patent and Trademark Office has upheld key claims of a U.S. patent directed to methods of treating type-1 hypersensitivity reactions, including anaphylaxis, using an epinephrine aqueous nasal spray. The company states that its global intellectual property portfolio related to neffy provides coverage until at least 2039.

In regulatory filings, ARS Pharmaceuticals, Inc. identifies itself as a Nasdaq-listed company with common stock trading under the symbol SPRY. The company and its subsidiaries have entered into a senior secured term loan facility with affiliates of RA Capital Management and OMERS Life Sciences, as described in a Form 8-K, to provide up to $250 million of term loans. ARS Pharma states that the proceeds are intended to fund research, development and other product development and commercialization activities of its products, including neffy, and for general corporate purposes. The obligations under the credit agreement are guaranteed by the company and certain subsidiaries and are secured by substantially all of their tangible and intangible assets, including intellectual property, subject to stated exceptions.

ARS Pharma also reports that it has received a Paragraph IV certification notice from Lupin Inc. regarding an Abbreviated New Drug Application seeking approval to manufacture and sell a generic version of neffy 2 mg (epinephrine nasal spray) prior to expiration of listed U.S. patents. The company has stated its intention to vigorously defend its intellectual property and to file a patent infringement suit seeking remedies including a permanent injunction to prevent introduction of a generic product that would infringe its patents.

Across its public communications, ARS Pharmaceuticals, Inc. consistently describes its core focus as the commercialization and further development of epinephrine nasal spray products for emergency treatment of Type I allergic reactions and anaphylaxis, along with clinical and real-world evidence programs intended to characterize the use of intranasal epinephrine in both community and clinical settings.